Literature DB >> 20056559

Clinical experience with miglustat therapy in pediatric patients with Niemann-Pick disease type C: a case series.

M Pineda1, M S Perez-Poyato, M O'Callaghan, M A Vilaseca, M Pocovi, R Domingo, L Ruiz Portal, A Verdú Pérez, T Temudo, A Gaspar, J J Garcia Peñas, S Roldán, L Martín Fumero, O Blanco de la Barca, M T García Silva, J Macías-Vidal, M J Coll.   

Abstract

Niemann-Pick disease type C (NP-C) is an inherited neurovisceral lysosomal lipid storage disease characterized by progressive neurological deterioration. Different clinical forms have been defined based on patient age at onset: perinatal, early-infantile (EI), late-infantile (Li), juvenile and adult. We evaluated the efficacy and tolerability of miglustat in 16 symptomatic NP-C patients, with comparative reference to one neurologically asymptomatic, untreated patient. All patients were categorized according to age at neurological disease onset, and were assessed using a standardized clinical assessment protocol: disability and cognitive function scales, positron emission tomography (PET), and biochemical markers. PET and disability scale evaluations indicated that cerebral hypometabolism and neurological symptoms were stabilized during treatment in juvenile-onset NP-C patients. EI and Li NP-C patients, who had higher disease severity at baseline (treatment start), showed increased disability scores and progressive cerebral hypometabolism during follow up. Similarly, while cognitive scale scores remained relatively stable in patients with juvenile NP-C, cognition deteriorated in EI and Li patients. Plasma chitotriosidase (ChT) activity was lower in the juvenile NP-C subgroup than in EI and Li patients, and generally increased in patients who discontinued treatment. Plasma CCL18/PARC and ChT activities indicated greater macrophagic activity in EI and Li patients versus juveniles. Miglustat was generally well tolerated; frequent adverse events included diarrhea and flatulence, which were managed effectively by dietary modification and loperamide. Overall, miglustat appeared to stabilize neurological status in juvenile-onset NP-C patients, but therapeutic benefits appeared smaller among younger patients who were at a more advanced stage of disease at baseline. Copyright 2009 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20056559     DOI: 10.1016/j.ymgme.2009.11.007

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  60 in total

1.  Characterization of a spontaneous novel mutation in the NPC2 gene in a cat affected by Niemann Pick type C disease.

Authors:  Stefania Zampieri; Ezio Bianchi; Carlo Cantile; Roberta Saleri; Bruno Bembi; Andrea Dardis
Journal:  PLoS One       Date:  2014-11-14       Impact factor: 3.240

2.  Niemann-Pick disease type C: analysis of 7 patients.

Authors:  Hui Xiong; Xin-Hua Bao; Yue-Hua Zhang; You-Ning Xu; Jiong Qin; Hui-Ping Shi; Xi-Ru Wu
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

Review 3.  Neuropsychological assessment in Niemann-Pick disease type C: a systematic review.

Authors:  Giuseppa Maresca; Caterina Formica; Vanessa Nocito; Desiree Latella; Simona Leonardi; Maria Cristina De Cola; Giuseppe Triglia; Placido Bramanti; Francesco Corallo
Journal:  Neurol Sci       Date:  2021-05-22       Impact factor: 3.307

Review 4.  Gastrointestinal disturbances and their management in miglustat-treated patients.

Authors:  Nadia Belmatoug; Alberto Burlina; Pilar Giraldo; Chris J Hendriksz; David J Kuter; Eugen Mengel; Gregory M Pastores
Journal:  J Inherit Metab Dis       Date:  2011-07-21       Impact factor: 4.982

5.  Long-term efficacy of miglustat in paediatric patients with Niemann-Pick disease type C.

Authors:  Y H Chien; S F Peng; C C Yang; N C Lee; L K Tsai; A C Huang; S C Su; C C Tseng; W L Hwu
Journal:  J Inherit Metab Dis       Date:  2012-04-05       Impact factor: 4.982

Review 6.  Miglustat: a review of its use in Niemann-Pick disease type C.

Authors:  Katherine A Lyseng-Williamson
Journal:  Drugs       Date:  2014-01       Impact factor: 9.546

7.  Dietary plant stanol ester supplementation reduces peripheral symptoms in a mouse model of Niemann-Pick type C1 disease.

Authors:  Inês Magro Dos Reis; Tom Houben; Yvonne Oligschläger; Leoni Bücken; Hellen Steinbusch; David Cassiman; Dieter Lütjohann; Marit Westerterp; Jos Prickaerts; Jogchum Plat; Ronit Shiri-Sverdlov
Journal:  J Lipid Res       Date:  2020-04-14       Impact factor: 5.922

8.  Sphingolipid signalling mediates mitochondrial dysfunctions and reduced chronological lifespan in the yeast model of Niemann-Pick type C1.

Authors:  Rita Vilaça; Elísio Silva; André Nadais; Vítor Teixeira; Nabil Matmati; Joana Gaifem; Yusuf A Hannun; Maria Clara Sá Miranda; Vítor Costa
Journal:  Mol Microbiol       Date:  2013-12-12       Impact factor: 3.501

Review 9.  Niemann-Pick disease type C.

Authors:  Marie T Vanier
Journal:  Orphanet J Rare Dis       Date:  2010-06-03       Impact factor: 4.123

Review 10.  Diagnostic workup and management of patients with suspected Niemann-Pick type C disease.

Authors:  Apostolos Papandreou; Paul Gissen
Journal:  Ther Adv Neurol Disord       Date:  2016-03-02       Impact factor: 6.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.